Crawley JN - Search Results

1

Hyperlocomotion induced by dopamine or cholecystokinin + dopamine in the nucleus accumbens is not modified by chronic lithium treatment.

Zohar J, Murphy DL, Crawley JN. Zohar J, et al. Among authors: crawley jn. Prog Neuropsychopharmacol Biol Psychiatry. 1989;13(5):775-9. doi: 10.1016/0278-5846(89)90064-x. Prog Neuropsychopharmacol Biol Psychiatry. 1989. PMID: 2675195

2

Reduced aggression in mice lacking the serotonin transporter.

Holmes A, Murphy DL, Crawley JN. Holmes A, et al. Among authors: crawley jn. Psychopharmacology (Berl). 2002 May;161(2):160-7. doi: 10.1007/s00213-002-1024-3. Epub 2002 Mar 22. Psychopharmacology (Berl). 2002. PMID: 11981596

3

Abnormal behavioral phenotypes of serotonin transporter knockout mice: parallels with human anxiety and depression.

Holmes A, Murphy DL, Crawley JN. Holmes A, et al. Among authors: crawley jn. Biol Psychiatry. 2003 Nov 15;54(10):953-9. doi: 10.1016/j.biopsych.2003.09.003. Biol Psychiatry. 2003. PMID: 14625137

4

Mice lacking the serotonin transporter exhibit 5-HT(1A) receptor-mediated abnormalities in tests for anxiety-like behavior.

Holmes A, Yang RJ, Lesch KP, Crawley JN, Murphy DL. Holmes A, et al. Among authors: crawley jn. Neuropsychopharmacology. 2003 Dec;28(12):2077-88. doi: 10.1038/sj.npp.1300266. Neuropsychopharmacology. 2003. PMID: 12968128

5

Abnormal anxiety-related behavior in serotonin transporter null mutant mice: the influence of genetic background.

Holmes A, Lit Q, Murphy DL, Gold E, Crawley JN. Holmes A, et al. Among authors: crawley jn. Genes Brain Behav. 2003 Dec;2(6):365-80. doi: 10.1046/j.1601-1848.2003.00050.x. Genes Brain Behav. 2003. PMID: 14653308 Free article.

6

Evaluation of antidepressant-related behavioral responses in mice lacking the serotonin transporter.

Holmes A, Yang RJ, Murphy DL, Crawley JN. Holmes A, et al. Among authors: crawley jn. Neuropsychopharmacology. 2002 Dec;27(6):914-23. doi: 10.1016/S0893-133X(02)00374-3. Neuropsychopharmacology. 2002. PMID: 12464448

7

Cholecystokinin-dopamine interactions.

Crawley JN. Crawley JN. Trends Pharmacol Sci. 1991 Jun;12(6):232-6. doi: 10.1016/0165-6147(91)90558-a. Trends Pharmacol Sci. 1991. PMID: 2048219 Review.

8

Attenuation of dark-induced hyperlocomotion by a cholecystokinin antagonist in the nucleus accumbens.

Crawley JN. Crawley JN. Brain Res. 1988 Nov 15;473(2):398-400. doi: 10.1016/0006-8993(88)90874-8. Brain Res. 1988. PMID: 3233498

9

Microdialysis as an approach to quantitate the release of neuropeptides.

De Mesquita S, Beinfeld MC, Crawley JN. De Mesquita S, et al. Among authors: crawley jn. Prog Neuropsychopharmacol Biol Psychiatry. 1990;14 Suppl:S5-15. doi: 10.1016/0278-5846(90)90083-s. Prog Neuropsychopharmacol Biol Psychiatry. 1990. PMID: 2097673

10

Neurotensin and cholecystokinin microinjected into the ventral tegmental area modulate microdialysate concentrations of dopamine and metabolites in the posterior nucleus accumbens.

Laitinen K, Crawley JN, Mefford IN, De Witte P. Laitinen K, et al. Among authors: crawley jn. Brain Res. 1990 Jul 23;523(2):342-6. doi: 10.1016/0006-8993(90)91511-e. Brain Res. 1990. PMID: 1698106

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

343 results

Search Page

Filters